JP6723930B2 - シグマ−１−受容体アゴニスト化合物の新規使用 - Google Patents
シグマ−１−受容体アゴニスト化合物の新規使用 Download PDFInfo
- Publication number
- JP6723930B2 JP6723930B2 JP2016568146A JP2016568146A JP6723930B2 JP 6723930 B2 JP6723930 B2 JP 6723930B2 JP 2016568146 A JP2016568146 A JP 2016568146A JP 2016568146 A JP2016568146 A JP 2016568146A JP 6723930 B2 JP6723930 B2 JP 6723930B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- tissue
- fibrosis
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14462004 | 2014-02-07 | ||
| EP14462004.4 | 2014-02-07 | ||
| PCT/HU2015/000014 WO2015118365A1 (en) | 2014-02-07 | 2015-02-09 | Novel use of sigma-1 receptor agonist compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509694A JP2017509694A (ja) | 2017-04-06 |
| JP2017509694A5 JP2017509694A5 (enExample) | 2018-03-22 |
| JP6723930B2 true JP6723930B2 (ja) | 2020-07-15 |
Family
ID=50241356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568146A Active JP6723930B2 (ja) | 2014-02-07 | 2015-02-09 | シグマ−１−受容体アゴニスト化合物の新規使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10124006B2 (enExample) |
| EP (1) | EP3104847B8 (enExample) |
| JP (1) | JP6723930B2 (enExample) |
| CN (1) | CN106456578B (enExample) |
| CA (1) | CA2938928C (enExample) |
| DK (1) | DK3104847T3 (enExample) |
| ES (1) | ES2848710T3 (enExample) |
| HR (1) | HRP20210114T1 (enExample) |
| HU (1) | HUE053165T2 (enExample) |
| IL (1) | IL247143B (enExample) |
| PL (1) | PL3104847T3 (enExample) |
| SI (1) | SI3104847T1 (enExample) |
| WO (1) | WO2015118365A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700448R1 (es) * | 2016-06-07 | 2019-02-26 | Esteve Pharmaceuticals Sa | Uso de ligandos del receptor sigma en la diabetes y el sindrome metabolico |
| DK3544420T3 (da) * | 2016-11-24 | 2022-09-05 | Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag | Anvendelse af sammensætninger til organ-/vævskonservering |
| US11071723B2 (en) * | 2017-10-20 | 2021-07-27 | Anavex Life Sciences Corp. | Treatment of cardiac dysfunction |
| EP3893892A4 (en) * | 2018-12-12 | 2022-09-14 | Rutgers, the State University of New Jersey | Organic compounds |
| CA3101853C (en) | 2019-02-14 | 2022-06-14 | Algernon Pharmaceuticals Inc. | Compositions and methods for treating idiopathic pulmonary fibrosis |
| JP7588773B2 (ja) | 2019-10-28 | 2024-11-25 | セイルテックス・インコーポレイテッド | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 |
| CN112386679B (zh) * | 2020-11-18 | 2023-05-30 | 徐州医科大学 | 一种包载sigma-1受体的外泌体在制备抗抑郁药物中的应用 |
| US20230263797A1 (en) * | 2021-08-26 | 2023-08-24 | Unm Rainforest Innovations | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States |
| CN118302423A (zh) * | 2022-11-04 | 2024-07-05 | 石药集团中奇制药技术（石家庄）有限公司 | 胺类化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| IN186677B (enExample) | 1999-11-12 | 2001-10-20 | Sun Pharmaceutical Ind Ltd | |
| WO2001062292A1 (en) | 2000-02-22 | 2001-08-30 | Suntory Limited | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| ES2291538T3 (es) * | 2001-11-13 | 2008-03-01 | Schering Corporation | Antagonistas de nk1. |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| EP1548008A4 (en) | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING |
| GB0715047D0 (en) | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel Compounds |
| DE102007063535A1 (de) * | 2007-12-21 | 2009-06-25 | Cycnad Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose |
| CA2741954A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| EP2391717A1 (en) | 2009-01-28 | 2011-12-07 | Aarhus Universitet | Treatment of radiation-induced fibrosis |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| WO2011146863A1 (en) * | 2010-05-21 | 2011-11-24 | Alcon Research, Ltd. | Surgical compositions containing sigma-receptor agonists |
| JP6069356B2 (ja) | 2012-01-05 | 2017-02-01 | クラノテク・アクチボラグ | 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物 |
-
2015
- 2015-02-09 JP JP2016568146A patent/JP6723930B2/ja active Active
- 2015-02-09 SI SI201531492T patent/SI3104847T1/sl unknown
- 2015-02-09 CA CA2938928A patent/CA2938928C/en active Active
- 2015-02-09 ES ES15715809T patent/ES2848710T3/es active Active
- 2015-02-09 DK DK15715809.8T patent/DK3104847T3/da active
- 2015-02-09 WO PCT/HU2015/000014 patent/WO2015118365A1/en not_active Ceased
- 2015-02-09 HR HRP20210114TT patent/HRP20210114T1/hr unknown
- 2015-02-09 EP EP15715809.8A patent/EP3104847B8/en active Active
- 2015-02-09 CN CN201580018235.6A patent/CN106456578B/zh active Active
- 2015-02-09 HU HUE15715809A patent/HUE053165T2/hu unknown
- 2015-02-09 PL PL15715809T patent/PL3104847T3/pl unknown
- 2015-02-09 US US15/117,233 patent/US10124006B2/en active Active
-
2016
- 2016-08-07 IL IL24714316A patent/IL247143B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3104847B1 (en) | 2020-11-11 |
| EP3104847B8 (en) | 2020-12-30 |
| DK3104847T3 (da) | 2021-02-01 |
| SI3104847T1 (sl) | 2021-07-30 |
| CA2938928C (en) | 2023-01-24 |
| EP3104847A1 (en) | 2016-12-21 |
| US20160346290A1 (en) | 2016-12-01 |
| IL247143B (en) | 2019-10-31 |
| CA2938928A1 (en) | 2015-08-13 |
| HUE053165T2 (hu) | 2021-06-28 |
| HRP20210114T1 (hr) | 2021-04-16 |
| JP2017509694A (ja) | 2017-04-06 |
| IL247143A0 (en) | 2016-09-29 |
| CN106456578A (zh) | 2017-02-22 |
| CN106456578B (zh) | 2020-02-18 |
| PL3104847T3 (pl) | 2021-07-05 |
| WO2015118365A1 (en) | 2015-08-13 |
| ES2848710T3 (es) | 2021-08-11 |
| US10124006B2 (en) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6723930B2 (ja) | シグマ−１−受容体アゴニスト化合物の新規使用 | |
| KR102647026B1 (ko) | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 | |
| EA030651B1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
| US9572787B2 (en) | Inhibition of renal fibrosis | |
| JP7457360B2 (ja) | 線維症の処置 | |
| KR20170141757A (ko) | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 | |
| US20240350494A1 (en) | Therapeutic modulation of integrins | |
| JP2021500362A (ja) | 進行性線維化を伴う間質性肺疾患（ｐｆ−ｉｌｄ）の処置のための活性剤の新規組み合わせ | |
| KR20200115547A (ko) | 섬유성 병리를 치료하는 방법 | |
| Zhang et al. | Asiatic acid from Cyclocarya paliurus regulates the autophagy–lysosome system via directly inhibiting TGF-β type I receptor and ameliorates diabetic nephropathy fibrosis | |
| US9376393B2 (en) | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | |
| US10842794B2 (en) | Use of Sigma-1 receptor agonist compounds | |
| JP2016506918A (ja) | イソメテプテン異性体 | |
| US10364230B2 (en) | Chromene-2 derivatives and use thereof in the treatment of fibrosis | |
| JP2004035475A (ja) | ＴＧＦβ作用抑制剤 | |
| US20250179167A1 (en) | Il-6 inhibitor as treatment for nephropathy | |
| KR20190068567A (ko) | 뇌 아밀로이드 혈관병증의 치료 또는 예방에 사용하기 위한 옥사진 유도체 | |
| WO2018226875A2 (en) | Methods and medicaments for the treatment of renal cell carcinoma | |
| KR102893133B1 (ko) | 진행성 섬유화 간질성 폐 질환(pf-ild)의 치료를 위한 활성 제제들의 신규한 배합 | |
| HK40066388A (en) | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof | |
| KR20250172732A (ko) | 진행성 섬유화 간질성 폐 질환(pf-ild)의 치료를 위한 활성 제제들의 신규한 배합 | |
| JP2012171907A (ja) | 新規ベンゾイソフラノン誘導体による臓器組織の修復再生治療薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161007 |
|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20161005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200609 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200624 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6723930 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |